Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 22, 2024
Daily News
March 22, 2024
- Japan Set to Push Central IRBs for Clinical Trials, Avoid Customary All-Case PMS
March 22, 2024
- Pharma Regulation Panel Wraps Up Debate, Report to Be Finalized Soon
March 22, 2024
- Japan, US CROs to Collaborate to Address Drug Lags/Losses
March 22, 2024
- Astellas Gives 1.5% Pay Raise to Acquire Best Talents
March 22, 2024
- 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
March 22, 2024
- FPMAJ Lays Out Planned Activities for FY2024
March 22, 2024
- Scrap Off-Year Drug Revision as It Mars Innovation, Supply: JPMA Official
March 22, 2024
- FDA Clears Orchard’s Lenmeldy Gene Therapy for MLD
March 22, 2024
- Japan Awards Orphan Tag to Janssen’s Talquetamab, 2 More APIs
March 22, 2024
- How to Paint an Irresistible Picture of Success
March 22, 2024
- Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
March 22, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…